A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor

NCT01994213 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

53

Enrollment

INDUSTRY

Sponsor class

Stopped The applicant decided to close the study

Conditions

Gastroenteropancreatic Neuroendocrine Tumor

Interventions

DRUG: Famitinib

Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Collaborators

[object Object]